

Patterns of Care: Examining the Current Use of Genetic Testing and Related Clinical Management for Patients with Localized Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III OlympiA trial evaluated olaparib versus placebo in the adjuvant setting for which population of patients with high-risk breast cancer and a germline BRCA mutation?
 - a. Patients with ER/PR-negative, HER2-negative breast cancer
 - b. Patients with ER/PR-positive, HER2-negative breast cancer
 - c. Patients with ER/PR-positive, HER2-positive breast cancer
 - d. All of the above
 - e. Both a and b
2. In the Phase III OlympiA trial evaluating olaparib versus placebo in the adjuvant setting for patients with high-risk breast cancer and a germline BRCA mutation, what was the duration of adjuvant olaparib therapy?
 - a. 6 months
 - b. 12 months
 - c. 18 months
 - d. 24 months
3. Results from the Phase III OlympiA trial demonstrated an improvement in which of the following endpoints with adjuvant olaparib for patients with high-risk breast cancer and a germline BRCA mutation?
 - a. Distant disease-free survival (DDFS)
 - b. Overall survival (OS)
 - c. Both DDFS and OS
 - d. Neither DDFS nor OS
4. Which of the following outcomes was reported regarding the development of myelodysplastic syndromes/acute myeloid leukemia (MDS/AML) as secondary cancer types associated with adjuvant olaparib in the Phase III OlympiA trial for patients with high-risk breast cancer and a germline BRCA mutation?
 - a. The rate of MDS/AML was higher than 5% in the adjuvant olaparib arm
 - b. The rate of MDS/AML was lower than 1% in the adjuvant olaparib arm
 - c. No cases of MDS/AML were observed in the adjuvant olaparib arm
5. An analysis of invasive disease-free survival (IDFS) by hormone receptor status in the Phase III OlympiA trial of adjuvant olaparib demonstrated which of the following outcomes?
 - a. Only patients with ER/PR-positive breast cancer experienced an improvement in IDFS
 - b. Only patients with ER/PR-negative breast cancer experienced an improvement in IDFS
 - c. Both patients with ER/PR-positive breast cancer and those with ER/PR-negative breast cancer experienced an improvement in IDFS